Studies measuring patient preference stacked up in subcutaneous administration’s favor, according to a recently published ...
The results showed that 26% of patients who received tulisokibart achieved clinical remission at week 12 compared with 1% of ...
The higher dose led to a more rapid decline in an important marker of neurodegeneration, according to a Biogen news release ...
More research on clinical meaningfulness is on the way, according to Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute and author of Investigating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback